Cell therapy biotech Arsenal Biosciences will lay off approximately 50% of its workforce as the company transitions to a clinical-stage company.
The company will lay off 100 workers from its South San Francisco location, effective mid-November 2025, according to a California WARN notice.
The clinical-stage programmable cell therapy company is focused on developing next-generation autologous T-cell therapies in oncology. Utilizing a proprietary biology toolkit, Arsenal looks to rewrite the programming of T-cells to overcome the multifaceted challenges presented by solid tumors. Its clinical pipeline includes AB-2100 in kidney cancer and multiple preclinical candidates for prostate cancer and other solid tumors, in addition to two partnered programs with Bristol Myers Squibb. In January 2025, BMS exercised its exclusive license option for ArsenalBio’s AB-4000 series, the lead collaboration program generated under the multi-program agreement.
The cash flow issue is somewhat unexpected for a company that closed an oversubscribed $325 million Series C financing round back in September 2024, making it one of the top cell therapy fundraisers of the year.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!